Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 88Carcinoma, Non-Small-Cell Lung 86Multiple Myeloma 73Prostatic Neoplasms 63Neoplasms 55Colorectal Neoplasms 46Lymphoma 42Squamous Cell Carcinoma of Head and Neck 41Leukemia, Myeloid, Acute 41Lung Neoplasms 39Pancreatic Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 31Ovarian Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 28Lymphoma, Non-Hodgkin 27Melanoma 26Head and Neck Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Sarcoma 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Hodgkin Disease 23Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Stomach Neoplasms 20Myelodysplastic Syndromes 20Lymphoma, Mantle-Cell 19

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Processes × 30 days × Clear all
NCT05797246 2026-05-22

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡